PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media287540ArticlesСтатьиResearch ArticleO protivoopukholevom effekte preparatov vitamina D3: fundamental'nye issledovaniya i dokazatel'naya meditsinaО противоопухолевом эффекте препаратов витамина D3: фундаментальные исследования и доказательная медицинаGromovaO. AГромоваО. А

д.м.н., проф. кафедры фармакологии и клинической фармакологии; зам. директора по научной работе

TorshinI. YuТоршинИ. Ю

к.х.н., зав. лабораторией вычислительной и системной биологии ; консультант

MalyginS. EМалыгинС. Е

доцент, кафедра онкологии и лучевой терапии

LimanovaO. AЛимановаО. А

к.м.н., доцент кафедры фармакологии и клинической фармакологии; научный консультант

Gilel'sA. VГилельсА. В

научный руководитель медицинской корпорации RHANA

ГБОУ ВПО «Ивановская государственная медицинская академия» МЗ РФРоссийский сотрудничающий центр Института микроэлементов ЮНЕСКО, МоскваФГБУН «Вычислительный центр им. А.А. Дородницына» РАН, МоскваГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава РоссииГБОУ ВПО «Ивановская государственная медицинская академия» МЗ РФРоссийский сотрудничающий центр Института микроэлементов ЮНЕСКО, МоскваМедицинская корпорация RHANA, Москва101020142119NO19 (2014)№19 (2014)485826022023Copyright ©; 2014, Bionika MediaCopyright ©; 2014, ООО «Бионика Медиа»2014Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/287540

Vitamin D is hormone involved in maintaining antitumor immunity. The article presents a comprehensive molecular and physiological model of antitumor effects of vitamin D. The data of evidence-based medicine, showing that long-term intake of vitamin D3 at doses of 800-1000 IU/day significantly reduces the risk of breast cancer, rectal cancer, and mortality from other forms of cancer, are discussed.

Витамин D - гормон, участвующий в поддержании противоопухолевого иммунитета организма. В работе представлена комплексная молекулярно-физиологическая модель противоопухолевого воздействия витамина D. Приведены данные доказательной медицины, свидетельствующие, что долговременный прием витамина D3 в дозировках 800-1000 МЕ/сут достоверно снижает риск рака молочной железы, толстого кишечника и смертность от других форм рака.

vitamin Dcancer preventionsystems biologybioinformaticsвитамин Dпрофилактика онкологических заболеванийсистемная биологиябиоинформатикаSaez M.E., Ramirez-Lorca R., Moron F.J., Ruiz A. The therapeutic potential of the calpain family: new aspects. Drug Discov. Today. 2006; 11(19-20): 917-23.Garland C.F., Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 1980; 9(3): 22 7-31.Ingraham B.A., Bragdon B., Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr. Med. Res. Opin. 2008; 24(1): 139-49.Никитинская О.А., Торопцова Н.В. Кальций и витамин D: анализ возможных положительных и отрицательных побочных явлений при их применении. РМЖ. 2011; 10: 651-55.Westerdahl J., Ingvar C., Masback A., et al. Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity. Br. J. Cancer. 2000; 82(9): 1593-99.Torshin I.Yu. Sensing the change from molecular genetics to personalized medicine. In «Bioinformatics in the Post-Genomic Era» series. Nova Biomedical Books, NY, USA, 2009.Nagpal S., Songqing N., Radhakrishnan R. Noncalcemic Actions of Vitamin D Receptor Ligands Full Text Endocrine Reviews. 2005; 5: 662-87.Yee Y.K., Chintalacharuvu S.R., Lu J., Nagpal S. Vitamin D receptor modulators for inflammation and cancer. Mini Rev. Med. Chem. 2005; 5(8): 761-78.Martin S. New agents in clinical oncology. Drugs. 2007; 10( 2): 99-101.Gilad L.A., Bresler T. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK1 /2 signaling pathway in colon and breast cancer cells. J. Endocrinol. 2005; 185(3): 577-92.Gilad L.A., Schwartz B. Association of estrogen receptor beta with plasma-membrane caveola components: implication in control of vitamin D receptor. J. Mol. Endocrinol. 2007; 38(6): 603.Abbas S., Linseisen J., Slanger T. Serum 25-hydroxyvitamin D and risk of postmenopausal breast cancer--results of a large case-control study. Carcinogenesis. 2008; 29(1): 93-9.Ding E.L., Mehta S., Fawzi W.W., Giovannucci E.L. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. Int. J. Cancer. 2008; 122(8): 1690-94.Lappe J.M., Travers-Gustafson D., Davies K.M. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 2007; 85(6): 1586-91.Torshin I.Yu. Bioinformatics in the post-genomic era: physiology and medicine. Nova Biomedical Books, NY, USA 2007: 35-67.Tuohimaa P. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur. J. Cancer. 2007; 43(11): 1701-12.Li H., Stampfer M.J., Hollis J.B. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007; 4(3): e103.Porojnicu A.C., Robsahm T.E. Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? Lung Cancer. 2007; 55(3): 263-70.Garland C.F., Gorham E.D., Mohr S.B., et al. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 2007; 103(3-5): 708-11.John E.M., Schwartz G.G., Koo J., et al. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 2005; 65(12): 5470-79.Knight J.A., Lesosky M., Barnett H., et al. Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 2007; 16(3): 422-29.Abbas S., Linseisen J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr. Cancer. 2007; 59(1): 54-61.Hartman T.J., Albert P.S., Snyder K., et al. The association of calcium and vitamin D with risk of colorectal adenomas. J. Nutr. 2005; 135(2): 252-59.Senesse P., Touvier M., Kesse E. Tobacco use and associations of beta-carotene and vitamin intakes with colorectal adenoma risk. J. Nutr. 2005; 135( 10): 2468-72.ИНВИТРО, http: //www.invitro.ru/analizes/for-doctors/487/2849/?sphrase_id=8963164 (обращение на сайт 27.07.2014).Ng K., Meyerhardt J.A., Wu K., Feskanich D. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J. Clin. Oncol. 2008; 26( 18): 2984-91.Wu K., Feskanich D., Fuchs C.S., et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J. Natl. Cancer Inst. 2007; 99(14): 1120-29.Gorham E.D., Garland C.F., Garland F.C., et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am. J. Prev. Med. 2007; 32(3): 210-16.Peters U., Hayes R.B. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev. 2004; 13(4): 546-52.Martinez M.E., Marshall J.R., Sampliner R., Wilkinson J., Alberts D.S. Calcium, vitamin D, and risk of adenoma recurrence (United States). Cancer Causes Control. 2002; 13(3): 213-20.Peters U., McGlynn K.A. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 2001; 10(12): 1267-74.Abbas S., Linseisen J., Slanger T.J. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol. Biomarkers Prev. 2008; 17(6): 1339-43.Trabert B., Malone K.E., Daling J.R., et al. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women. Breast Cancer Res. 2007; 9(6): R84.Li C., Liu Z., Zhang Z., et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J. Invest. Dermatol. 2007; 127(2): 276-80.Sillanpaa P., Hirvonen A., Kataja V. Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk. Pharmacogenetics. 2004; 14(4): 239-45.Zhang K., Song L. Association between vitamin D receptor gene polymorphisms and breast cancer risk: a meta-analysis of 39 studies. PLoS One. 2014; 9(4): e96125.Ahn J., Yu K., Stolzenberg-Solomon R., et al. Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumour Biol. 2013; 34(6): 3509-17.Wang D., Velez de-la-Paz O.I., Zhai J.X., Liu D.W. Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumour Biol. 2013; 34(6): 3509-17.Bauer S.R., Hankinson S.E., Bertone-Johnson E.R., Ding E.L. Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine. (Baltimore) 2013; 92(3): 123-31.Chen P., Li M., Gu X., et al. Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies. PLoS One. 2013; 8(1): e49312.Hong Z., Tian C., Zhang X. Dietary calcium intake, vitamin D levels, and breast cancer risk: a dose-response analysis of observational studies. Breast Cancer Res. Treat. 2012; 1 36(1): 309-12.Mohr S.B., Gorham E.D., Alcaraz J.E., et al. Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res. 2011; 31(9): 2939-48.Chen P., Hu P., Xie D., et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res. Treat. 2010; 121(2): 469-77.Chung M., Lee J., Terasawa T., et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2011; 155(12): 827-38.Yin L., Grandi N., Raum E., et al. Meta-analysis: Serum vitamin D and colorectal adenoma risk. Prev. Med. 2011; 53(1-2): 10-6.Lee J.E., Li H., Chan A.T., et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev. Res. (Phila). 2011; 4(5): 735-43.Touvier M., Chan D.S., Lau R., Aune D. Metaanalyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2011; 20(5): 1003-16.Lagunova Z., Porojnicu A.C. Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol. Nutr. Food Res. 2010; 54(8): 1127-33.Schottker B., Jorde R., Peasey A., et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ. 2014; 348: g3656.Keum N., Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br. J. Cancer. 2014; 101038/bjc2014294.Yin L., Ordonez-Mena J.M., Chen T., et al. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Prev. Med. 2013; 57(6): 753-64.Zheng Y., Zhu J., Zhou M., et al. Meta-analysis of long-term vitamin D supplementation on overall mortality. PLoS One. 2013; 8(12): e8210.Kim Y., Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br. J. Cancer. 2014; 110(11): 2772-84.Громова О.А., Торшин И.Ю., Лиманова О.А., Громов А.Н., Керимкулова Н.В. Сравнительное исследование доказательной базы эффективности и безопасности применения пероральной и трансдермальной форм заместительной гормональной терапии эстрогенами у женщин в различные возрастные периоды. Проблемы репродукции. 2013; 6: 86-96.